{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T10:53:41Z","timestamp":1764240821961,"version":"build-2065373602"},"reference-count":55,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Prolactin levels have been shown to influence metabolic outcomes, including insulin resistance. Metformin is known to be beneficial in polycystic ovary syndrome (PCOS) patients. PCOS women might react differently to metformin treatment depending on their baseline prolactin levels. Methods: In this retrospective study, the homeostasis model assessment for insulin resistance (HOMA-IR), prolactin, luteinizing hormone (LH), follicle-stimulating hormone (FSH), the LH:FSH ratio, and total testosterone and sex hormone-binding globulin (SHBG) were measured in 75 obese\/overweight women with PCOS and insulin resistance before initiation of metformin treatment and after 6\u20138 months. Results: At baseline, HOMA-IR was inversely correlated to SHBG (r = \u22120.408; p &lt; 0.001) and prolactin (r = \u22120.402; p &lt; 0.001). After 6\u20138 months of metformin treatment, the LH:FSH ratio and the HOMA-IR declined significantly (p &lt; 0.05). A significant positive correlation could be shown between basal prolactin and the difference in the HOMA-IR (r = 0.233; p = 0.044). Women with lower baseline prolactin (\u226414.9 ng\/mL) revealed a sharper decline in HOMA-IR (\u22120.8, IQR \u22121.0; \u22120.5 vs. \u22120.6, IQR \u22120.8; \u22120.3; p = 0.049) as well as an increase in prolactin at follow-up (1.6 ng\/mL, IQR \u22120.2;3.8 vs. \u22121.3, IQR \u22124.6;3.2; p = 0.003) compared to patients with a baseline prolactin &gt; 14.9 ng\/mL. Conclusions: In overweight\/obese, insulin-resistant PCOS women, lower baseline prolactin levels are associated with higher baseline HOMA-IR levels as well as with a better response to metformin treatment. More data are necessary to prove these observations in larger populations.<\/jats:p>","DOI":"10.3390\/jcm13247781","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T07:42:18Z","timestamp":1734680538000},"page":"7781","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Changes in Prolactin and Insulin Resistance in PCOS Patients Undergoing Metformin Treatment: A Retrospective Study"],"prefix":"10.3390","volume":"13","author":[{"given":"Tal","family":"Goldstein","sequence":"first","affiliation":[{"name":"Klinik Favoriten, 1100 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2761-5262","authenticated-orcid":false,"given":"Johannes","family":"Ott","sequence":"additional","affiliation":[{"name":"Clinical Division of Gynecological Endocrinology and Reproductive Medicine, Department of Obstetrics and Gynecology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Katzensteiner","sequence":"additional","affiliation":[{"name":"Clinical Division of Gynecological Endocrinology and Reproductive Medicine, Department of Obstetrics and Gynecology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5454-2620","authenticated-orcid":false,"given":"Robert","family":"Krysiak","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1772-6695","authenticated-orcid":false,"given":"Rodrig","family":"Marculescu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Boegl","sequence":"additional","affiliation":[{"name":"Clinical Division of Gynecological Endocrinology and Reproductive Medicine, Department of Obstetrics and Gynecology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0012-9029","authenticated-orcid":false,"given":"Marlene","family":"Hager","sequence":"additional","affiliation":[{"name":"Clinical Division of Gynecological Endocrinology and Reproductive Medicine, Department of Obstetrics and Gynecology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Chen, W., and Pang, Y. (2021). Metabolic Syndrome and PCOS: Pathogenesis and the Role of Metabolites. Metabolites, 11.","DOI":"10.3390\/metabo11120869"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1093\/humrep\/dead156","article-title":"Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome","volume":"38","author":"Teede","year":"2023","journal-title":"Hum. Reprod."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/tog.12519","article-title":"Metabolic syndrome in women with polycystic ovary syndrome","volume":"20","author":"Chandrasekaran","year":"2018","journal-title":"Obstet. Gynaecol."},{"key":"ref_4","first-page":"56","article-title":"Metformin use in women with polycystic ovary syndrome","volume":"2","author":"Johnson","year":"2014","journal-title":"Ann. Transl. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/2042018810380215","article-title":"Role of metformin in the management of polycystic ovary syndrome","volume":"1","author":"Lashen","year":"2010","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.pathophys.2013.03.002","article-title":"Body weight reduction and metformin: Roles in polycystic ovary syndrome","volume":"20","author":"Habib","year":"2013","journal-title":"Pathophysiology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/er.2008-0030","article-title":"Evidence-Based and Potential Benefits of Metformin in the Polycystic Ovary Syndrome: A Comprehensive Review","volume":"30","author":"Palomba","year":"2009","journal-title":"Endocr. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/bmj.327.7421.951","article-title":"Metformin in polycystic ovary syndrome: Systematic review and meta-analysis","volume":"327","author":"Lord","year":"2003","journal-title":"BMJ"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s12020-019-02170-x","article-title":"Low prolactin levels are associated with visceral adipocyte hypertrophy and insulin resistance in humans","volume":"67","author":"Ponce","year":"2020","journal-title":"Endocrine"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.2337\/dc12-1893","article-title":"Circulating prolactin associates with diabetes and impaired glucose regulation: A population-based study","volume":"36","author":"Wang","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Yang, H., Lin, J., Li, H., Liu, Z., Chen, X., and Chen, Q. (2021). Prolactin is associated with insulin resistance and beta-cell dysfunction in infertile women with polycystic ovary syndrome. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.571229"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s12020-015-0655-1","article-title":"Is prolactin the missing link in adipose tissue dysfunction of polycystic ovary syndrome patients?","volume":"51","author":"Albu","year":"2016","journal-title":"Endocrine"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Macotela, Y., Ruiz-Herrera, X., V\u00e1zquez-Carrillo, D.I., Ram\u00edrez-Hernandez, G., Mart\u00ednez de la Escalera, G., and Clapp, C. (2022). The beneficial metabolic actions of prolactin. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.1001703"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Krysiak, R., Kowalcze, K., Szkr\u00f3bka, W., and Okopie\u0144, B. (2023). Impaired Prolactin-Lowering Effects of Metformin in Women with Polycystic Ovary Syndrome. J. Clin. Med., 12.","DOI":"10.3390\/jcm12175474"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod., 19, 41\u201347.","DOI":"10.1093\/humrep\/deh098"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.fertnstert.2018.05.004","article-title":"Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"110","author":"Teede","year":"2018","journal-title":"Fertil. Steril."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1093\/humrep\/dex308","article-title":"Insulin resistance in a large cohort of women with polycystic ovary syndrome: A comparison between euglycaemic-hyperinsulinaemic clamp and surrogate indexes","volume":"32","author":"Tosi","year":"2017","journal-title":"Hum. Reprod."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/09513590.2021.2016692","article-title":"Dydrogesterone after 60 years: A glance at the safety profile","volume":"38","author":"Ott","year":"2022","journal-title":"Gynecol. Endocrinol."},{"key":"ref_19","unstructured":"(2022). Medical laboratories\u2014Requirements for Quality and Competence (Standard No. ISO 15189)."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Boegl, M., Dewailly, D., Marculescu, R., Steininger, J., Ott, J., and Hager, M. (2024). The LH:FSH Ratio in Functional Hypothalamic Amenorrhea: An Observational Study. J. Clin. Med., 13.","DOI":"10.3390\/jcm13051201"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00404-019-05194-w","article-title":"The impact of a standardized micronutrient supplementation on PCOS-typical parameters: A randomized controlled trial","volume":"300","author":"Hager","year":"2019","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00404-023-07277-1","article-title":"Prolactin levels in functional hypothalamic amenorrhea: A retrospective case-control study","volume":"309","author":"Selzer","year":"2024","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00592-013-0493-7","article-title":"Age dependent association of serum prolactin with glycaemia and insulin sensitivity in humans","volume":"51","author":"Wagner","year":"2014","journal-title":"Acta Diabetol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1007\/s43032-021-00535-0","article-title":"Evaluation of the Efficacy of Sex Hormone-Binding Globulin in Insulin Resistance Assessment Based on HOMA-IR in Patients with PCOS","volume":"28","author":"Chen","year":"2021","journal-title":"Reprod. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"T\u0171\u0171, L., Nas, K., T\u00f6r\u00f6k, M., and V\u00e1rb\u00edr\u00f3, S. (2024). SHBG Levels Do Not Correlate with Insulin Levels in PCOS with Appropriate Fasting Insulin Sensitivity. J. Clin. Med., 13.","DOI":"10.3390\/jcm13030838"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s42000-020-00219-5","article-title":"Efficacy of sex hormone-binding globulin on predicting metabolic syndrome in newly diagnosed and untreated patients with polycystic ovary syndrome","volume":"19","author":"Fu","year":"2020","journal-title":"Hormones"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1467-789X.2012.01053.x","article-title":"The effect of obesity on polycystic ovary syndrome: A systematic review and meta-analysis","volume":"14","author":"Lim","year":"2013","journal-title":"Obes. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1210\/jcem-67-3-460","article-title":"Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin","volume":"67","author":"Plymate","year":"1988","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.cca.2019.09.010","article-title":"Sex hormone-binding globulin and polycystic ovary syndrome","volume":"499","author":"Zhu","year":"2019","journal-title":"Clin. Chim. Acta"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/09513590902770172","article-title":"Metformin administration was associated with a modification of LH, prolactin and insulin secretion dynamics in women with polycystic ovarian syndrome","volume":"25","author":"Billa","year":"2009","journal-title":"Gynecol. Endocrinol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.25122\/jml-2023-0317","article-title":"Effects of combined metformin and cabergoline versus metformin alone on ovarian and hormonal activities in Iraqi patients with PCOS and hyperprolactinemia: A randomized clinical trial","volume":"16","author":"Hamad","year":"2023","journal-title":"J. Med. Life"},{"key":"ref_32","first-page":"93","article-title":"Cabergoline plus metformin therapy effects on menstrual irregularity and androgen system in polycystic ovary syndrome women with hyperprolactinemia","volume":"13","author":"Ghaneei","year":"2015","journal-title":"Iran. J. Reprod. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s13224-017-1022-3","article-title":"Efficacy of combined cabergoline and metformin compared to metformin alone on cycle regularity in patients with polycystic ovarian disease with hyperprolactinemia: A randomized clinical trial","volume":"67","author":"Elsersy","year":"2017","journal-title":"J. Obstet. Gynecol. India"},{"key":"ref_34","first-page":"79","article-title":"Male equivalent polycystic ovarian syndrome: Hormonal, metabolic, and clinical aspects","volume":"14","author":"Ciotta","year":"2020","journal-title":"Int. J. Fertil. Steril."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1002\/jcph.2088","article-title":"Pituitary effects of metformin in men with early-onset androgenic alopecia","volume":"62","author":"Krysiak","year":"2022","journal-title":"J. Clin. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/bcpt.13307","article-title":"Endogenous testosterone determines metformin action on prolactin levels in hyperprolactinaemic men: A pilot study","volume":"126","author":"Krysiak","year":"2020","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1179558119871921","DOI":"10.1177\/1179558119871921","article-title":"PCOS and Hyperprolactinemia: What do we know in 2019?","volume":"13","author":"Delcour","year":"2019","journal-title":"Clin. Med. Insights Reprod. Health"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2265.1986.tb00759.x","article-title":"Studies of prolactin secretion in polycystic ovary syndrome","volume":"24","author":"Murdoch","year":"1986","journal-title":"Clin. Endocrinol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF03350674","article-title":"Prolactin pulsatility in polycystic ovarian disease","volume":"8","author":"Laatikainen","year":"1985","journal-title":"J. Endocrinol. Investig."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2265.1988.tb01208.x","article-title":"Episodic pulsatile secretion of FSH, LH, prolactin, oestradiol, oestrone, and LH circadian variations in polycystic ovary syndrome","volume":"28","author":"Venturoli","year":"1988","journal-title":"Clin. Endocrinol."},{"key":"ref_41","first-page":"436","article-title":"Inhibition of luteinizing hormone release by dopamine infusion in healthy women and in various pathophysiologi- cal conditions","volume":"97","author":"Ferrari","year":"1981","journal-title":"Acta Endocrinol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1210\/jcem-43-3-668","article-title":"Effects of dopamine infusion on pituitary hormone secretion in humans","volume":"43","author":"Leblanc","year":"1976","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1210\/jcem-56-5-889","article-title":"Effect of dopamine on gonadotropin- releasing hormone-induced gonadotropin secretion in postmenopausal women","volume":"56","author":"Pehrson","year":"1983","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1210\/jcem-52-2-231","article-title":"Increased luteinizing hormone sensitivity to dopamine inhibition in polycystic ovary syndrome","volume":"52","author":"Quigley","year":"1981","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1210\/jcem-61-4-779","article-title":"Central opioid activity in polycystic ovary syndrome with and without dopaminergic modulation","volume":"61","author":"Barnes","year":"1985","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1210\/jcem-63-2-506","article-title":"Effects of dopa- mine and metoclopramide in polycystic ovary syndrome","volume":"63","author":"Barnes","year":"1986","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1210\/jcem-63-1-119","article-title":"A double blind controlled study of the hormonal and clinical effects of bromocriptine in the polycystic ovary syndrome","volume":"63","author":"Buvat","year":"1986","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1210\/jcem-62-5-1048","article-title":"The effect of bromocrip- tine on gonadotropin and steroid secretion in polycystic ovarian disease","volume":"62","author":"Steingold","year":"1986","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"16057","DOI":"10.1038\/nrdp.2016.57","article-title":"Polycystic ovary syndrome","volume":"2","author":"Azziz","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_50","first-page":"141","article-title":"Physiopathological link between polycystic ovary syndrome and hyperprolactinemia: Myth or reality?","volume":"39","author":"Robin","year":"2011","journal-title":"GynecolObstetFertil"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ando.2007.03.008","article-title":"Prolactinoma and estro- gens: Pregnancy, contraception and hormonal replacement therapy","volume":"68","author":"Delemer","year":"2007","journal-title":"Ann. Endocrinol."},{"key":"ref_52","first-page":"1","article-title":"Physiologie de la prolactine","volume":"11","author":"Touraine","year":"2015","journal-title":"EMC-Gyn\u00e9cologie"},{"key":"ref_53","first-page":"671","article-title":"The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with patho- logical hyperprolactinemia","volume":"59","author":"Corenblum","year":"1993","journal-title":"FertilSteril"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0010-7824(98)00069-9","article-title":"Two-year treatment with oral contraceptives in hyperprolactinemic patients","volume":"58","author":"Testa","year":"1998","journal-title":"Contraception"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/humrep\/12.3.423","article-title":"Clinical and hormonal effects of the combina- tion gonadotrophin-releasing hormone agonist plus oral contraceptive pills con- taining ethinyl-oestradiol (EE) and cyproterone acetate (CPA) versus the EE-CPA pill alone on polycystic ovarian disease-related hyperandrogenisms","volume":"12","author":"Mauri","year":"1997","journal-title":"Hum. Reprod."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/24\/7781\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:56:05Z","timestamp":1760115365000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/24\/7781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":55,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["jcm13247781"],"URL":"https:\/\/doi.org\/10.3390\/jcm13247781","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2024,12,20]]}}}